Protagonist Therapeutics (NASDAQ:PTGX) Given New $100.00 Price Target at TD Cowen

Protagonist Therapeutics (NASDAQ:PTGX) had its price objective upped by equities researchers at TD Cowen from $90.00 to $100.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s target price would indicate a potential upside of 15.05% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Truist Financial lifted their price target on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a report on Monday, January 5th. Jefferies Financial Group upped their target price on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. JPMorgan Chase & Co. increased their price target on Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings downgraded Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, February 17th. Finally, Citigroup increased their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $99.31.

Protagonist Therapeutics Trading Down 0.2%

Protagonist Therapeutics stock traded down $0.18 during trading on Thursday, reaching $86.92. The company had a trading volume of 261,479 shares, compared to its average volume of 723,181. The firm has a market capitalization of $5.43 billion, a price-to-earnings ratio of 140.42 and a beta of 2.26. The firm’s 50-day simple moving average is $84.07 and its 200 day simple moving average is $76.51. Protagonist Therapeutics has a 52 week low of $35.95 and a 52 week high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%.The company had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. On average, analysts predict that Protagonist Therapeutics will post 2.43 earnings per share for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Lewis T. Williams sold 18,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total value of $1,483,560.00. Following the sale, the director owned 7,825 shares of the company’s stock, valued at $644,936.50. The trade was a 69.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director William D. Waddill sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $83.68, for a total value of $1,673,600.00. Following the sale, the director directly owned 7,825 shares in the company, valued at $654,796. This trade represents a 71.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 203,167 shares of company stock worth $16,889,199 over the last three months. 4.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC increased its holdings in shares of Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the last quarter. Greenline Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at approximately $27,000. Salomon & Ludwin LLC purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter worth approximately $29,000. Bessemer Group Inc. increased its position in shares of Protagonist Therapeutics by 171.0% during the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after purchasing an additional 318 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Protagonist Therapeutics by 138.9% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after buying an additional 314 shares during the period. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics News Summary

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Barclays raised its price target to $113 and maintained an “overweight” rating, implying ~31% upside versus the recent price. Benzinga
• Positive Sentiment: Citizens Jmp raised its target to $112 and gave a “market outperform” rating, signaling analyst confidence in upside (~30% from the recent price). Benzinga
• Positive Sentiment: Corporate update / corrected press release: Protagonist said it submitted an NDA for rusfertide to the FDA (potential approval/launch this year), expects to likely opt out of a 50:50 profit/loss sharing arrangement with Takeda in a Q2 window, expects a U.S. regulatory decision for ICOTYDE (icotrokinra) in 2026, and plans PN-881 Phase 1 completion by mid-2026 while expanding preclinical pipeline — items that materially increase near- and mid-term commercial upside if approvals proceed. Correction / Corporate Update
• Neutral Sentiment: Company posted its formal fourth-quarter and full-year 2025 results and corporate update (full release available). This provides official detail that investors will parse for guidance and cash runway. Press Release
• Negative Sentiment: Q4 results disappointed: EPS of ($0.69) missed consensus (-$0.53) and revenue was $7.44M vs. $14.92M expected — the shortfall raises near-term execution and revenue questions. Earnings Release
• Negative Sentiment: Hedge fund BVF disclosed a large Q4 exit (sold ~2.56M PTGX shares, ~$170M), which can increase downward pressure on the stock and signal profit-taking by an institutional holder. Fool Coverage

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.